What is Deciphera?
Deciphera is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for cancer patients. The company leverages its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to build a robust portfolio of therapeutic candidates. Deciphera's approved product, QINLOCK®, is a switch-control kinase inhibitor indicated for the treatment of fourth-line gastrointestinal stromal tumor (GIST), with additional approvals in several international markets. The company's strategic approach involves advancing multiple product candidates through clinical studies, aiming to address unmet needs in oncology.
How much funding has Deciphera raised?
Deciphera has raised a total of $994.5M across 6 funding rounds:
Series B
$90M
Series C
$52M
Stock Offering
$127.5M
Stock Offering
$400M
Stock Offering
$175M
Stock Offering
$150M
Series B (2015): $90M with participation from SV Life Sciences and New Leaf Venture Partners
Series C (2017): $52M led by Viking Global Investors, Redmile Group, New Leaf Venture Partners, and Sphera Global Healthcare Fund
Stock Issuance/Offering (2017): $127.5M, investors not publicly disclosed
Stock Issuance/Offering (2019): $400M, investors not publicly disclosed
Stock Issuance/Offering (2020): $175M, investors not publicly disclosed
Stock Issuance/Offering (2022): $150M, investors not publicly disclosed
Key Investors in Deciphera
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies. Viking is headquartered in Greenwich, Connecticut, with offices in New York, Hong Kong, London, and San Francisco.
New Leaf Venture Partners
New Venture Partners LLC, the global venture capital firm dedicated to corporate technology spinouts, has over $700 million under management. New Venture Partners provides a bridge between technology corporations and traditional venture capital. Through its unique, hands-on approach, the firm offers a systematic process for commercializing innovations and provides an alternative path to market for corporate technologies.
SV Life Sciences
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
What's next for Deciphera?
With its substantial enterprise-level funding and recent strategic investment, Deciphera is poised for accelerated growth and pipeline expansion. The capital infusion is anticipated to fuel further clinical development of its promising drug candidates, potentially leading to new therapeutic approvals and market entries. Deciphera's focus on kinase inhibitor technology positions it to address complex cancer pathways, and this latest financing will be critical in navigating the rigorous drug development process and bringing new treatments to patients.
See full Deciphera company page
